Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
Ashleigh McEvoy, Edith Cowan UniversityFollow
Michelle R. Pereira
Muhammad A. Khattak
Tarek M. Meniawy
Mel R. Ziman Dr, Edith Cowan UniversityFollow
Elin S. Gray, Edith Cowan UniversityFollow
BioMed Central Ltd
School of Medical and Health Sciences
Background: Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of metastatic disease. Therefore, there is a need to understand the correlation between ctDNA levels and the patients' overall metabolic tumour burden (MTB). Methods: Thirty-two treatment naïve metastatic melanoma patients were included in the study. MTB and metabolic tumour volume (MTV) was measured by 18F-fluoro-D-glucose positron emission tomography/computed tomography (FDG PET/CT). Plasma ctDNA was quantified using droplet digital PCR (ddPCR). Results: CtDNA was detected in 23 of 32 patients. Overall, a significant correlation was observed between ctDNA levels and MTB (p
McEvoy, A. C. (2018). Circulating tumour DNA: A non-invasive biomarker for melanoma. https://ro.ecu.edu.au/theses/2064
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
McEvoy, A. C., Warburton, L., Al-Ogaili, Z., Celliers, L., Calapre, L., Pereira, M. R., ... & Gray, E. S. (2018). Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC cancer, 18(1), 726. Available here.